Navigation Links
Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
Date:10/27/2008

s respectively. The infusion reaction

experience in the GOUT 3 study was consistent and similar in nature and

pattern to that observed in the GOUT 1 and GOUT 2 studies and was

easily managed utilizing the methods specified in the study protocols.

As previously reported in GOUT 1, GOUT 2 and GOUT 3, there were a total

of seven patient deaths in the clinical program: 5 (5/169 or 3%) in

pegloticase treatment groups and two (2/44 or 4.5%) in the placebo

groups.

- Of these seven deaths, 3 were attributed to cardiac events. Two of

the events occurred in the pegloticase arms and one in the placebo

group as previously reported by the Company and not believed to be

drug related.

Cardiovascular Serious Adverse Events (SAEs) in patients on pegloticase

GOUT 1 and GOUT 2 were as follows:

- There were two reported cardiac SAEs which were included among the

seven deaths indicated above.

- A third patient who was on pegloticase every 4 weeks, following a

placebo dose had an SAE relating to congestive heart failure which

was resolved after hospitalization. However, as previously

reported, this patient died of renal failure after voluntarily

withdrawing from renal dialysis.

- The remaining five patients with cardiac SAEs continued to receive

pegloticase in the trials. It is important to note that all five

patients continued treatment successfully despite their

cardiovascular event.

None of these cardiovascular events, including the patient deaths were

thought to be causally related to pegloticase treatment by the

Investigators and Sponsor.

We believe the overall safety profile of pegloticase in the clinical

program indicates that long-term administration of 8 mg pegloticase in<
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
2. Intensive Lifestyle Intervention Program for Overweight or Obese Patients with Nonalcoholic Steatohepatitis Reduces Weight and Improves Overall Liver Health
3. UKs NICE Recommends Spinal Cord Stimulation for Patients with Chronic Neuropathic Pain
4. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
5. AdvanDxs PNA FISH(TM) Test Shown to Reduce Mortality by 42% for Patients With Hospital-Acquired Enterococcus faecium Bloodstream Infections
6. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
7. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
8. Novel Mass Spectrometry-based Assay Reveals Degradation and Low Levels of Bioactive B-type Natriuretic Peptide (BNP) in Patients with Heart Failure
9. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
10. DaVita Treats Thousands of Dialysis Patients in Wake of Hurricane Ike
11. Fujitsu PalmSecure and HT Systems PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... PA (PRWEB) May 06, 2015 Tenney, ... most comprehensive lines of standard and custom environmental ... for its innovative engineering and design, robust construction, and ... is designed to meet all of your temperature, humidity, ... announce the addition of the TPS Smart 1.0 Controller. ...
(Date:5/6/2015)... , May 6, 2015 ... fuel membrane specialist, announced today that it has signed ... based Pacific Ethanol, Inc. (Nasdaq: PEIX ) for the delivery ... to reduce the consumption of water, energy ... product output. This project is ...
(Date:5/5/2015)... CAMBRIDGE, Mass. , May 5, 2015 /PRNewswire/ ... the closing of its initial public offering of ... offering price of $18.00 per share, including shares ... by the underwriters of their option to purchase ... public offering to Blueprint Medicines were approximately $168.6 million, ...
(Date:5/5/2015)... Hayden-McNeil is pleased to announce they ... for smaller courses. This program is specifically designed for ... , “I’m very excited about offering our publishing ... said Jeff McCarthy, Hayden-McNeil president. “By working with more ... to make education both more effective and affordable.” , ...
Breaking Biology Technology:The TPS 3.5” Smart 1.0 Controller Raises the Tech Standard on Environmental Test Chambers 2Whitefox Signs Agreement With Pacific Ethanol Inc. 2Blueprint Medicines Announces Closing of Initial Public Offering 2Hayden-McNeil Expands Publishing Program to Service Lower Enrollment Courses 2
... Management Solution innovating the way Misukanis & Odden schedule tasks. ... ... Technologies ( http://info.oneplacehome.com ), creators of the ground breaking ... with their video series "A Day In The Life." The newest ...
... Corporation,(Nasdaq: DRRX ) announced today that ... Alpharma Ireland Limited, an affiliate of,Alpharma Inc. ... the exclusive worldwide,rights to develop and commercialize ... review under the,Hart-Scott-Rodino (HSR) Antitrust Improvements Act ...
... Professors Ichijo and Mano Receive 2008 JCA-Mauvernay ... Debiopharm Group,(Debiopharm), a global biopharmaceutical development specialist ... oncology, presented,Professors Hidenori Ichijo and Hiroyuki Mano ... basic and applied research work in oncology.,The ...
Cached Biology Technology:Riverock Technologies Helps Misukanis & Odden Eliminate Task Management Obstacles 2Riverock Technologies Helps Misukanis & Odden Eliminate Task Management Obstacles 3DURECT's Collaboration With Alpharma Clears HSR Review and Is Effective 2DURECT's Collaboration With Alpharma Clears HSR Review and Is Effective 3DURECT's Collaboration With Alpharma Clears HSR Review and Is Effective 4Japanese Cancer Association and Debiopharm Honour Japanese Research 2Japanese Cancer Association and Debiopharm Honour Japanese Research 3
(Date:4/1/2015)... OXFORD, Conn. , Apr. 1, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... number of Wocket smart wallets is underway to early ... early access group includes usage at retail outlets including ... CVS Pharmacy. Users report Wocket was accepted at all ...
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... - A Purdue University biochemist has demonstrated a process ... their targets, which may help reduce drug side effects. ... analytical chemistry, developed a nanopolymer that can be coated ... which proteins in the cells the drug has entered. ...
... now open! ,You may apply for a Press ... www.eular.org/congress_press_registration.cfm Scientific Programme , The scientific ... The preliminary programme can be accessed online or downloaded ... Abstracts , Abstracts accepted for presentation are made available ...
... Recycling manure is an important practice, especially for large ... in crop production, aiding livestock producers that grow their own ... for crops, it also can contribute to nutrient leaching and ... eutrophication of waterways. The desire for farmers to be able ...
Cached Biology News:Nanopolymer shows promise for helping reduce cancer side effects 2EULAR 2011 media update 2Cost effective manure management 2
... a magnetic bead-based PCR purification ... transfer, centrifugation or filtration steps. ... large PCR extension products in ... AMPure can easily be performed ...
... is a magnetic bead-based PCR ... sample transfer, centrifugation or filtration ... and large PCR extension products ... Agencourt AMPure can easily be ...
... This kit is designed for the fast ... vector plasmids at any position (for the ... loxP-PGK-gb2-neo-loxP cassette is designed to allow neomycin ... cells. It combines a prokaryotic promoter (gb2) ...
Includes a choice of any 3 EasySep mouse selection kits and EasySep magnet...
Biology Products: